Titan Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Titan Biotech CEO'su Naresh Singla, Apr2018 tarihinde atandı, in görev süresi 6.58 yıldır. in toplam yıllık tazminatı ₹ 4.80M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.54% ine doğrudan sahiptir ve bu hisseler ₹ 35.07M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.2 yıl ve 2.1 yıldır.

Anahtar bilgiler

Naresh Singla

İcra Kurulu Başkanı

₹4.8m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	6.6yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	5.2yrs
Yönetim Kurulu ortalama görev süresi	2.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Naresh Singla'un ücretlendirmesi Titan Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹253m
Jun 30 2024	n/a	n/a	₹251m
Mar 31 2024	₹5m	₹5m	₹249m
Dec 31 2023	n/a	n/a	₹248m
Sep 30 2023	n/a	n/a	₹209m
Jun 30 2023	n/a	n/a	₹227m
Mar 31 2023	₹5m	₹5m	₹248m
Dec 31 2022	n/a	n/a	₹249m
Sep 30 2022	n/a	n/a	₹268m
Jun 30 2022	n/a	n/a	₹249m
Mar 31 2022	₹5m	₹5m	₹217m
Dec 31 2021	n/a	n/a	₹241m
Sep 30 2021	n/a	n/a	₹255m
Jun 30 2021	n/a	n/a	₹263m
Mar 31 2021	₹5m	₹5m	₹303m
Dec 31 2020	n/a	n/a	₹285m
Sep 30 2020	n/a	n/a	₹236m
Jun 30 2020	n/a	n/a	₹178m
Mar 31 2020	₹5m	₹5m	₹71m
Dec 31 2019	n/a	n/a	₹58m
Sep 30 2019	n/a	n/a	₹49m
Jun 30 2019	n/a	n/a	₹46m
Mar 31 2019	₹4m	₹4m	₹35m

Tazminat ve Piyasa: Naresh 'nin toplam tazminatı ($USD 56.94K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 42.72K ).

Tazminat ve Kazançlar: Naresh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Naresh Singla (65 yo)

6.6yrs

Görev süresi

₹4,800,000

Tazminat

Mr. Naresh Kumar Singla serves as Managing Director of Titan Biotech Limited since April 1, 2018 and its Director since February 18, 1992. Mr. Singla joined the Titan Biotech Limited on February 18, 1992....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Naresh Singla	MD & Executive Director	6.6yrs	₹4.80m	0.54% ₹ 35.1m
Suresh Singla	MD & Executive Director	6.6yrs	₹4.80m	1.28% ₹ 83.3m
Prem Gupta	Chief Financial Officer	no data	₹1.85m	Veri yok
Charanjit Singh	Company Secretary	no data	₹2.27m	Veri yok
Raja Singla	Senior VP of Production & Whole Time Director	5.2yrs	₹12.00m	0.74% ₹ 48.1m
Udit Singla	Whole Time Director	1.1yrs	₹6.00m	0.61% ₹ 39.4m
Shivom Singla	Whole Time Director	1.1yrs	₹6.00m	0.43% ₹ 27.9m
Madhu Singla	Vice President of Admn.	no data	Veri yok	Veri yok

5.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: 524717 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Naresh Singla	MD & Executive Director	32.8yrs	₹4.80m	0.54% ₹ 35.1m
Suresh Singla	MD & Executive Director	32.8yrs	₹4.80m	1.28% ₹ 83.3m
Raja Singla	Senior VP of Production & Whole Time Director	2.1yrs	₹12.00m	0.74% ₹ 48.1m
Udit Singla	Whole Time Director	1.1yrs	₹6.00m	0.61% ₹ 39.4m
Shivom Singla	Whole Time Director	1.1yrs	₹6.00m	0.43% ₹ 27.9m
Manju Singla	Non-Executive Woman Director	23.4yrs	Veri yok	0.86% ₹ 56.1m
Supriya Singla	Non-Executive Non-Independent Director	12.1yrs	Veri yok	0.66% ₹ 42.9m
Rohit Jain	Non-Executive Independent Chairman	3.3yrs	Veri yok	Veri yok
Abhishek Agarwal	Independent Non-Executive Director	2.1yrs	₹34.50k	Veri yok
Dhairya Madan	Independent Non-executive Director	1.1yrs	₹30.00k	Veri yok
Brijesh Singh	Independent Non-executive Director	1.1yrs	₹30.00k	Veri yok

2.1yrs

Ortalama Görev Süresi

35yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 524717 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Titan Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Titan Biotech Limited, Annual General Meeting, Sep 30, 2024

Titan Biotech Limited, Annual General Meeting, Sep 29, 2023

Titan Biotech Limited Announces Resignation of Rekha Dalmia as Non-Executive Independent Director

Less than half of directors are independent

Titan Biotech Limited Appoints Raja Singla as Executive Director, with Effect from October 1, 2022

Titan Biotech Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Second quarter 2025 earnings released: EPS: ₹8.10 (vs ₹7.89 in 2Q 2024)

Titan Biotech Limited to Report Q2, 2025 Results on Nov 12, 2024

Investor sentiment improves as stock rises 23%

Upcoming dividend of ₹2.00 per share

Investor sentiment improves as stock rises 25%

Dividend increased to ₹2.00

Titan Biotech Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹7.74 (vs ₹7.47 in 1Q 2024)

Titan Biotech Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings released: EPS: ₹30.07 (vs ₹30.06 in FY 2023)

Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2024

Investor sentiment improves as stock rises 19%

Titan Biotech Limited to Report Q4, 2024 Results on May 29, 2024

Investor sentiment improves as stock rises 28%

Third quarter 2024 earnings released: EPS: ₹8.68 (vs ₹3.95 in 3Q 2023)

New minor risk - Share price stability

Titan Biotech Limited to Report Q3, 2024 Results on Feb 12, 2024

Investor sentiment improves as stock rises 24%

Second quarter 2024 earnings released: EPS: ₹7.89 (vs ₹11.04 in 2Q 2023)

Upcoming dividend of ₹1.80 per share at 0.5% yield

Full year 2023 earnings released: EPS: ₹25.44 (vs ₹30.66 in FY 2022)

Titan Biotech Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Financial data availability

Investor sentiment improves as stock rises 27%

Titan Biotech Limited to Report Q1, 2024 Results on Aug 10, 2023

Titan Biotech Limited Announces Resignation of Rekha Dalmia as Non-Executive Independent Director

Titan Biotech Limited Recommends Dividend for the Financial Year Ended on March 31, 2023

Titan Biotech Limited to Report Q4, 2023 Results on May 29, 2023

Third quarter 2023 earnings released: EPS: ₹3.95 (vs ₹6.33 in 3Q 2022)

Titan Biotech Limited to Report Q3, 2023 Results on Feb 04, 2023

Second quarter 2023 earnings released: EPS: ₹11.04 (vs ₹7.74 in 2Q 2022)

Less than half of directors are independent

Now 21% undervalued

Titan Biotech Limited to Report Q2, 2023 Results on Nov 14, 2022

Titan Biotech Limited Appoints Raja Singla as Executive Director, with Effect from October 1, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings released: EPS: ₹30.66 (vs ₹36.71 in FY 2021)

Titan Biotech Limited, Annual General Meeting, Sep 30, 2022

Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹1.50 per share

Independent Non Executive Chairman Jai Bansal has left the company

First quarter 2022 earnings released: EPS ₹10.56 (vs ₹15.42 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹36.71 (vs ₹8.55 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹202

Investor sentiment improved over the past week

New 90-day high: ₹192

Third quarter 2021 earnings released: EPS ₹8.02 (vs ₹2.13 in 3Q 2020)

Titan Biotech Limited to Report Q3, 2021 Results on Jan 27, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: ₹126

Market pulls back on stock over the past week

First half earnings released

New 90-day high: ₹185

Market bids up stock over the past week

Titan Biotech Limited to Report Q2, 2020 Results on Oct 19, 2020

Upcoming Dividend of ₹1.00 Per Share

Insider recently sold ₹1.8m worth of stock

Earnings released

New 90-day high - ₹89.65

CEO Tazminat Analizi